JP3990728B2 - Ｎ−［４−オキソ−２−（１ｈ−テトラゾール−５−イル）−４ｈ−１−ベンゾピラン−８−イル］−４−（４−フェニルブトキシ）ベンズアミドの塩 - Google Patents
Ｎ−［４−オキソ−２−（１ｈ−テトラゾール−５−イル）−４ｈ−１−ベンゾピラン−８−イル］−４−（４−フェニルブトキシ）ベンズアミドの塩 Download PDFInfo
- Publication number
- JP3990728B2 JP3990728B2 JP51629297A JP51629297A JP3990728B2 JP 3990728 B2 JP3990728 B2 JP 3990728B2 JP 51629297 A JP51629297 A JP 51629297A JP 51629297 A JP51629297 A JP 51629297A JP 3990728 B2 JP3990728 B2 JP 3990728B2
- Authority
- JP
- Japan
- Prior art keywords
- salt
- compound
- composition
- phenylbutoxy
- benzopyran
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- NBQKINXMPLXUET-UHFFFAOYSA-N Pranlukast Chemical class C=1C=C(OCCCCC=2C=CC=CC=2)C=CC=1C(=O)NC1=CC=CC(C(C=2)=O)=C1OC=2C=1N=NNN=1 NBQKINXMPLXUET-UHFFFAOYSA-N 0.000 title description 3
- 150000003839 salts Chemical class 0.000 claims description 29
- 239000000203 mixture Substances 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 208000006673 asthma Diseases 0.000 claims description 5
- 159000000000 sodium salts Chemical group 0.000 claims description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 4
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 4
- 150000001298 alcohols Chemical group 0.000 claims description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 239000011591 potassium Substances 0.000 claims description 3
- 229910052700 potassium Inorganic materials 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- 239000007983 Tris buffer Substances 0.000 claims description 2
- 125000003158 alcohol group Chemical group 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 150000002334 glycols Chemical class 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
- 229940125904 compound 1 Drugs 0.000 description 17
- 239000002904 solvent Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 8
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 150000003863 ammonium salts Chemical class 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229920000604 Polyethylene Glycol 200 Polymers 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 description 1
- 239000001639 calcium acetate Substances 0.000 description 1
- 235000011092 calcium acetate Nutrition 0.000 description 1
- 229960005147 calcium acetate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Chemical group OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 238000012306 spectroscopic technique Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9521490.4 | 1995-10-20 | ||
| GB9521491.2 | 1995-10-20 | ||
| GBGB9521491.2A GB9521491D0 (en) | 1995-10-20 | 1995-10-20 | Novel formulations |
| GBGB9521490.4A GB9521490D0 (en) | 1995-10-20 | 1995-10-20 | Novel formulations |
| PCT/EP1996/004650 WO1997015569A1 (en) | 1995-10-20 | 1996-10-18 | Salts of n-(4-oxo-2-(1h-tetrazoyl-5-yl)-4h-1-benzopyran-8-yl)-4-(4-phenylbutoxy)benzamide |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JPH11513701A JPH11513701A (ja) | 1999-11-24 |
| JPH11513701A5 JPH11513701A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 2004-09-16 |
| JP3990728B2 true JP3990728B2 (ja) | 2007-10-17 |
Family
ID=26307980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP51629297A Expired - Lifetime JP3990728B2 (ja) | 1995-10-20 | 1996-10-18 | Ｎ−［４−オキソ−２−（１ｈ−テトラゾール−５−イル）−４ｈ−１−ベンゾピラン−８−イル］−４−（４−フェニルブトキシ）ベンズアミドの塩 |
Country Status (17)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100683274B1 (ko) * | 2004-02-12 | 2007-02-15 | 에스케이케미칼주식회사 | 치환된 벤조피란 화합물의 제조방법 |
| KR100716274B1 (ko) * | 2006-10-02 | 2007-05-09 | 에스케이케미칼주식회사 | 치환된 벤조피란 화합물 합성용 화합물 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1261835A (en) * | 1984-08-20 | 1989-09-26 | Masaaki Toda | (fused) benz(thio)amides |
-
1996
- 1996-10-17 AR ARP960104785A patent/AR004029A1/es unknown
- 1996-10-18 AU AU74924/96A patent/AU7492496A/en not_active Abandoned
- 1996-10-18 PL PL96326501A patent/PL326501A1/xx unknown
- 1996-10-18 TR TR1998/00705T patent/TR199800705T2/xx unknown
- 1996-10-18 ES ES96937239T patent/ES2188797T3/es not_active Expired - Lifetime
- 1996-10-18 WO PCT/EP1996/004650 patent/WO1997015569A1/en active IP Right Grant
- 1996-10-18 JP JP51629297A patent/JP3990728B2/ja not_active Expired - Lifetime
- 1996-10-18 AT AT96937239T patent/ATE229525T1/de not_active IP Right Cessation
- 1996-10-18 HU HU9900727A patent/HUP9900727A3/hu unknown
- 1996-10-18 CA CA002235396A patent/CA2235396A1/en not_active Abandoned
- 1996-10-18 DE DE69625379T patent/DE69625379T2/de not_active Expired - Fee Related
- 1996-10-18 KR KR1019980702845A patent/KR19990064341A/ko not_active Withdrawn
- 1996-10-18 CZ CZ981180A patent/CZ118098A3/cs unknown
- 1996-10-18 US US09/051,879 patent/US6028092A/en not_active Expired - Fee Related
- 1996-10-18 BR BR9611236A patent/BR9611236A/pt not_active Application Discontinuation
- 1996-10-18 EP EP96937239A patent/EP0873337B1/en not_active Expired - Lifetime
-
1998
- 1998-04-17 NO NO981741A patent/NO981741L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR9611236A (pt) | 1999-05-04 |
| ES2188797T3 (es) | 2003-07-01 |
| EP0873337A1 (en) | 1998-10-28 |
| TR199800705T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1998-09-21 |
| EP0873337B1 (en) | 2002-12-11 |
| NO981741D0 (no) | 1998-04-17 |
| WO1997015569A1 (en) | 1997-05-01 |
| NO981741L (no) | 1998-05-25 |
| HUP9900727A2 (hu) | 1999-08-30 |
| HUP9900727A3 (en) | 1999-11-29 |
| US6028092A (en) | 2000-02-22 |
| JPH11513701A (ja) | 1999-11-24 |
| DE69625379T2 (de) | 2003-08-21 |
| CZ118098A3 (cs) | 1998-09-16 |
| PL326501A1 (en) | 1998-09-28 |
| AU7492496A (en) | 1997-05-15 |
| DE69625379D1 (de) | 2003-01-23 |
| KR19990064341A (ko) | 1999-07-26 |
| AR004029A1 (es) | 1998-09-30 |
| ATE229525T1 (de) | 2002-12-15 |
| CA2235396A1 (en) | 1997-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2260428C2 (ru) | Фармацевтическая композиция, содержащая производное бензамида и обладающая повышенной растворимостью и поглощаемостью при оральном применении | |
| CA2098302C (en) | Medicaments | |
| JP2568401B2 (ja) | 水溶性メグルミン塩及びグルカミン塩、その製造方法並びにこれを含有する医薬組成物 | |
| EA021826B1 (ru) | Усовершенствованный способ синтеза пирфенидона | |
| JP3411038B2 (ja) | ミコフェノール酸モフェチルの結晶質無水物およびその静注用製剤 | |
| CN100518726C (zh) | 莫达非尼化合物的药用溶液 | |
| BR112019018615B1 (pt) | Composto antimicrobiano e sua composiqao farmaceutica | |
| PT100671B (pt) | Sal de l-ascorbato de 16-descarboxi-16-hidroxi-metilanfotericina b e processo para a sua preparacao | |
| JP2002505328A (ja) | 抗潰瘍医薬の硝酸塩 | |
| AU599034B2 (en) | Furosemide salts | |
| JP2011511803A (ja) | 置換ベンゾオキサゾールのホスファート誘導体 | |
| KR20110026311A (ko) | 엔테카비어의 신규한 염 | |
| JP3990728B2 (ja) | Ｎ−［４−オキソ−２−（１ｈ−テトラゾール−５−イル）−４ｈ−１−ベンゾピラン−８−イル］−４−（４−フェニルブトキシ）ベンズアミドの塩 | |
| NL8101987A (nl) | De verbinding 4-amino-1-beta-d-ribofuranosyl-1h-imidazo/4.5-c/-pyridine of een farmaceutisch aanvaardbaar zuuradditiezout daarvan; farmaceutisch preparaat. | |
| AU615245B2 (en) | Aqueous formulations containing a piperidinylcyclopentylheptenoic acid derivative | |
| CZ20021433A3 (cs) | Proléčivo na bázi 6-methoxy-2-naftyloctové kyseliny | |
| JPS6350355B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | ||
| WO2005023803A1 (en) | Phosphoric acid salt of 5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl] methyl]- 2,4-thiazolidinedione | |
| CN1204333A (zh) | N－(4－氧代－2－(1h－四唑－5－基)－4h－1－苯并吡喃－8－基)－4－(4－苯基丁氧基)苯甲酰胺的盐 | |
| EP1713476A2 (en) | Rabeprazole containing formulation | |
| WO2025179296A1 (en) | Crystalline forms of nu-3 and uses thereof | |
| MXPA98003099A (en) | Benzamide salts n- (4-oxo-2 (1h-tetrazoil-5-il) -4h-1-benzopiran-8-il) -4- (4-fenilbuto) | |
| CZ285693A3 (en) | Cephalosporin salts and process for preparing thereof | |
| JPH02500671A (ja) | 抗乾癬医薬組成物の調製方法 | |
| JPH04221379A (ja) | チアプロフェン酸又はその不溶性若しくは部分可溶性エステルとシクロデキストリン又はそれらの誘導体との新規な複合体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070220 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070516 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070703 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070723 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100727 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110727 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110727 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120727 Year of fee payment: 5 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130727 Year of fee payment: 6 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |